within Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AC03_Chloropyramine;
model Chloropyramine 
   extends Pharmacolibrary.Drugs.ATC.R.R06AC03;

  annotation(Documentation(
    info ="<html><body><p>Chloropyramine is a first-generation antihistamine belonging to the ethylenediamine class. It acts as a histamine H1 receptor antagonist and is primarily used to treat allergic conditions such as urticaria, allergic rhinitis, and pruritus. Although it has been widely used in some countries, its use has largely decreased in favor of newer antihistamines due to central nervous system side effects and anticholinergic properties. It is still used in some Eastern European countries.</p><h4>Pharmacokinetics</h4><p>No comprehensive pharmacokinetic studies in humans are publicly available. The following values are reasonable estimates for an adult population based on class properties and limited secondary data sources.</p><h4>References</h4><ol><li><p>Wilton, J, et al., &amp; Fetterly, G (2016). Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. <i>European journal of drug metabolism and pharmacokinetics</i> 41(1) 55–67. DOI:<a href=&quot;https://doi.org/10.1007/s13318-014-0233-6&quot;>10.1007/s13318-014-0233-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25377246/&quot;>https://pubmed.ncbi.nlm.nih.gov/25377246</a></p></li><li><p>Bender, KI, &amp; Lutsevich, AN (1988). [Dependence of the absorption through the human oral mucosa of antihistaminic (H1) preparations on their physicochemical properties]. <i>Farmakologiia i toksikologiia</i> 51(1) 75–79. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2896132/&quot;>https://pubmed.ncbi.nlm.nih.gov/2896132</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Chloropyramine;
